[HTML][HTML] Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
K Peris, MC Fargnoli, C Garbe, R Kaufmann… - European Journal of …, 2019 - Elsevier
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations.
Multidisciplinary experts from the European Dermatology Forum, the European Association …
Multidisciplinary experts from the European Dermatology Forum, the European Association …
[HTML][HTML] Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline
A Stratigos, C Garbe, C Lebbe, J Malvehy… - European journal of …, 2015 - Elsevier
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in
Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique …
Caucasian populations, accounting for 20% of all cutaneous malignancies. A unique …
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer
S Madhusudan, MR Middleton - Cancer treatment reviews, 2005 - Elsevier
Advanced cancer is the second leading cause of death in the western world. Chemotherapy
and radiation are the two main treatment modalities currently available to improve patient …
and radiation are the two main treatment modalities currently available to improve patient …
[HTML][HTML] Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
RHI Andtbacka, HL Kaufman, F Collichio… - Journal of clinical …, 2015 - iro.uiowa.edu
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic
immunotherapy designed to selectively replicate within tumors and produce granulocyte …
immunotherapy designed to selectively replicate within tumors and produce granulocyte …
[HTML][HTML] Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …
approved for the treatment of advanced melanoma. In the United States, ipilimumab has …
[HTML][HTML] Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey… - … England Journal of …, 2012 - Mass Medical Soc
Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are
found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy …
found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy …
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma …
JP Neoptolemos, MJ Moore, TF Cox, JW Valle… - Jama, 2012 - jamanetwork.com
Context Patients with periampullary adenocarcinomas undergo the same resectional
surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant …
surgery as that of patients with pancreatic ductal adenocarcinoma. Although adjuvant …
[PDF][PDF] Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 …
JW Valle, D Palmer, R Jackson, T Cox… - Journal of clinical …, 2014 - openaccessrepository.it
Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal
Adenocarcinoma of the Pancreas: Ongoing Page 1 Optimal Duration and Timing of Adjuvant …
Adenocarcinoma of the Pancreas: Ongoing Page 1 Optimal Duration and Timing of Adjuvant …
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised …
PA Ascierto, M Del Vecchio, M Mandalá… - The Lancet …, 2020 - thelancet.com
Summary Background Previously, findings from CheckMate 238, a double-blind, phase 3
adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed …
adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed …
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial
W Greenhalf, P Ghaneh… - Journal of the …, 2014 - academic.oup.com
Background Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …
adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after …